NCT00970411

Study of KRN951 in Patients With Solid Tumors

An Open-label, Non-randomised Dose Escalation Study of KRN951 Administered Orally to Patients With Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Kyowa Kirin Co., Ltd. · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of KRN951 administered to patients with solid tumors. In the single dose period, patients in each cohort will receive one oral dose of KRN951 in the first day, followed by a 6-day rest period during which no treatment is received. After that, patients in each cohort will receive one oral dose of KRN951 daily over a 21-day treatment period, followed by a 7-day rest period during which no treatment is received. Treatment will be continued in the absence of disease progression or unacceptable adverse events.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	KRN951	Orally once daily administration

Timeline

• Start date: 2009-08-01
• Primary completion: 2016-04-01
• Completion: 2016-04-01
• First posted: 2009-09-02
• Last updated: 2017-01-05

Locations

1 site across 1 country: Japan